Edwards Lifesciences has been under scrutiny regarding its stock performance as compared to other indices such as the Dow and Nasdaq. The company has been dealing with a class action lawsuit, which has urged investors of
EW to get in touch with law firms for representation. There were positive notes from Jim Cramer, who noted on several occasions that EW was in a good zone and was a hold. The company’s earnings reports have indicated strong sales growth, especially in TMTT sales. Despite analysts questioning whether Edwards Lifesciences’ stock should remain in your portfolio or whether it was overbought, there were promising signs such as an elevation by an analyst as a top pick and upgrades to its stock price target by Citi. The company has been given clearance by the
FDA for its
TAVR therapy for asymptomatic patients and a positive growth strategy was outlined at an Investor Conference. There are allegations of securities fraud that have initiated lawsuits which could lead to shareholders leading class action. Despite these challenges,
Q1 earnings and revenues beat market expectations with raised sales view projected for 2025, receiving upgrades from Piper Sandler and Baird along with price target increases.
Edwards Lifesciences Corp EW News Analytics from Mon, 15 Jul 2024 07:00:00 GMT to Fri, 06 Jun 2025 15:05:00 GMT -
Rating 3
- Innovation 6
- Information 7
- Rumor -7
